Morepen Labs Baddi facility clears USFDA inspection without any adverse observation
Advertisement
Gurugram: Morepen Labs has recently announced that the United States Food and Drug Administration (USFDA) has conducted an inspection of the API manufacturing facility, at Baddi, Himachal Pradesh, of the company.
"The facility has been cleared by USFDA on 24th March 2023 without any adverse observation (NIL 483)," the company stated in a BSE filing.
Read also: Morepen Labs forms new subsidiary for medical devices
Morepen Labs is a pharmaceutical company headquartered in New Delhi. The company was founded in 1984. With a strong global presence, Morepen exports to over 75 countries with certifications from all major regulatory authorities like USFDA, WHO GMP, EU GMP.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.